Firefly Neuroscience

Firefly Neuroscience

Firefly Neuroscience emerged as a publicly traded entity focused on neurology diagnostics, with Jon Olsen serving as CEO. The company operates at the intersection of digital health and artificial intelligence, developing tools to standardize how brain function is measured and monitored. Its core asset is the Brain Network Analytics platform, which received FDA 510(k) clearance to evaluate electroencephalogram data using proprietary algorithms. The firm's platform quantifies brain activity across multiple neural networks, producing reports designed to aid clinicians in diagnosing and managing conditions including major depressive disorder, Alzheimer's disease, and traumatic brain injury. Firefly deploys its technology through a software-as-a-service model distributed to neurologists and psychiatrists, with a geographic focus on the United States market. The company has pursued reimbursement codes from the Centers for Medicare & Medicaid Services to support clinical adoption. Confirmed partnerships include a collaboration with the University of South Florida to study concussion detection. Firefly operates with a lean structure typical of a commercial-stage life-sciences firm, with its team concentrated on engineering, regulatory affairs, and commercial rollout. In April 2024, Firefly completed a merger with WaveDancer, a publicly listed shell company, gaining a Nasdaq listing under the ticker symbol AIFF. The transaction provided access to public capital markets to fund further deployment of its diagnostic platform. The firm occupies an unusual space on the public markets — a pure-play AI diagnostics company with FDA clearance, not a drug developer. This regulatory moat, combined with a subscription-based software revenue model, distinguishes it from the capital-intensive biotechnology firms that dominate the neurology sector. The company's future posture will depend on its ability to secure broad insurance reimbursement and integrate its analytics into routine psychiatric care pathways.